46 reports

influenza antiviral drugs and antiphospholipid antibody assays Focuses on the commercialization of microarraybased diagnostic tests that provide early detection of neurodegenerative diseases, cancer, and other chronic diseases Develops novel proprietary diagnostic tests in the area of clini

  • Immunochemistry Test
  • Laboratory
  • Abbott Laboratories, Inc.
  • Danaher Corporation
  • Roche Group
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine

Involves in the manufacture of diagnostic products and tests for fusion-inhibiting entry-inhibiting influenza antiviral drugs and antiphospholipid antibody assays.

  • Autoimmune Disease
  • Diagnostics
  • World
  • EUROIMMUN AG
  • Roche Group
  • PARTNERSHIPS AMRI ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH BIOTA HOLDINGS FOR CS8958
  • PARTNERSHIPS
  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Aviragen Therapeutics, Inc.
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

ANNOUNCED THAT ANTI-INFLUENZA DRUG CANDIDATES UNDER ITS FLUCIDE PROGRAM, WHEN GIVEN ORALLY, LED TO STRONG ANTIVIRAL ANTIBODY RESPONSE.

  • Healthcare
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Daiichi Sankyo Company Ltd - History

In May, Daiichi Sankyo Company, Limited entered into a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute for its influenza HA vaccine " Kaketsuken" .

  • Healthcare
  • Pharmaceutical
  • Japan
  • Company Financials
  • Daiichi Sankyo Company
  • Pharmaceutical Market, Chemical Company of Malaysia, Global, Major Products, 2016

REFERENCE CODE GDHC##CHR| PUBLICATION DATE SEPTEMBER 2016 HEALTHCARE, REGULATORY AND REIMBURSEMENT LANDSCAPE - MALAYSIA Executive Summary The pharmaceutical market of Malaysia has significant potential for growth.

  • Healthcare
  • Mortality
  • Pharmaceutical
  • Asia
  • Malaysia
  • 9.3 BIBLIOGRAPHY

Clinical implications of antiviral resistance in influenza.

  • Clinical Trial
  • Influenza
  • Pathology
  • Therapy
  • Vaccine

Antiviral Therapy Targeting Viral Polymerase.

  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • Vaccine
  • World
  • PARTNERSHIPS
  • PARTNERSHIPS

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Healthcare
  • Pharmaceutical
  • United States
  • Company Financials
  • AMRI
  • LANINAMIVIR - DRUG PROFILE

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • LANINAMIVIR - DRUG PROFILE

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Healthcare
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine

The emergence of various new influenza A viruses cause an influenza pandemic.

  • Diagnostics
  • Influenza
  • Alere Inc.
  • bioMerieux S.A.
  • Quidel Corporation
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • Therapy
  • Vaccine
  • United States
  • Novavax, Inc.
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • ALBANY MOLECULAR RESEARCH
  • AKULA TRADING 2 PTY
  • Healthcare
  • Hospital
  • Pharmaceutical
  • United States
  • Wildwood Ventures Limited

THE UK RECOMMENDS THE USE OF ANTIVIRALS DEPENDING UPON THE CIRCULATION OF SEASONAL FLU AND INITIATES STOCKPILING OF ANTI-INFLUENZA DRUGS TO SECURE PUBLIC HEALTH DURING THE OUTBREAK OF VIRAL PANDEMIC.

  • Antiviral
  • HIV AIDS
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc

Also embedded in the lipid membrane is the M## protein, which is the target of the antiviral adamantanes - amantadine and rimantadine.

  • Healthcare
  • Influenza
  • Pathology
  • Vaccine
  • Europe
  • PARTNERSHIP - DEAL REPORTS

a US-based contract research and manufacturing organization, has signed an agreement with Biota Holdings Limited, to further develop and manufacture Biota' s influenza antiviral CS## (laninamivir), a second-generation, long-acting neuraminidase inhibitor.

  • Pharmaceutical
  • Respiratory Treatment
  • United States
  • Company
  • AMRI

The best way to prevent flu is to get the flu vaccine.

  • Healthcare
  • Influenza
  • Pathology
  • Vaccine
  • Europe
  • RESPIRATORY SYNCYTIAL VIRUS (RSV) - OPPORTUNITY ANALYSIS AND FORECASTS TO 2024

" [Adamantane] influenza antivirals had resistance develop very quickly on therapy...

  • Epidemiology
  • Therapy
  • Vaccine
  • Ablynx NV
  • Gilead Sciences, Inc.
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • NAS-911 - DRUG PROFILE

In July 2014, New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS-## as a co-therapeutic for existing influenza antivirals currently available to flu patients.

  • Biotech
  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • FEATURED NEWS & PRESS RELEASES

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • R&D
  • Research And Development
  • Vaccine
  • NanoViricides, Inc.
  • H1N1 Infection - Product Development Milestones

As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals.

  • Influenza
  • Pharmaceutical
  • R&D
  • Research And Development
  • Vaccine
  • Clinical Trial Profile Snapshots

PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE EFFECTIVENESS (EAVE) - USE OF A UNIQUE COMMUNITY AND LABORATORY NATIONAL LINKED DATASET: AN OBSERVATIONAL LONGITUDINAL COHORT STUDY WITH NESTED-CASE CONTROL STUDY EARLY ESTIMATION OF PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE

  • Clinical Trial
  • Drug Discovery And Development
  • Influenza
  • Pathology
  • Vaccine
  • 10.2. DEALS BY PRECLINICAL STAGE

antiviral vaccines Collaborative R& D agreement for AVE ## safety and tolerability Licensing agreement for tkRNAi technology Grant award for Parkinson' s disease research Yes Apr 2012 BioVest, US Army Medical Research Institute of Infectious Diseases Sanofi, Michael J Fox Foundatio

  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Wildwood Ventures Limited
  • PARTNERSHIP - DEAL REPORTS
  • DEAL REPORT: BIOTA SCIENTIFIC RECEIVES BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) CONTRACT
  • Pharmaceutical
  • United Kingdom
  • United States
  • Company
  • Biota Holdings Limited

Also embedded in the lipid membrane is the M## protein, which is the target of the antiviral adamantanes - amantadine and rimantadine.

  • Healthcare
  • Influenza
  • Pathology
  • Vaccine
  • Europe